Clinical Trial Update: Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for dalantercept in squamous cell carcinoma of the head and neck has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• dalantercept (dalantercept)

Snippet

Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Conditions: Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Status: COMPLETED | Results posted: 2017-06-27